因子XI或XIa抑制剂患者的围手术期管理
本文综述因子XI(FXI)及FXIa抑制剂这类新型抗凝药的围手术期管理。FXI缺乏患者的手术数据及已完成的2期临床试验围术期数据提示,抑制FXI可在降低静脉血栓栓塞风险的同时减少临床相关出血,并可能实现不中断用药的简化围术期方案。
要点
- FXI/FXIa抑制剂抑制内源性通路,抗栓同时不破坏止血。
- 重度FXI缺乏患者手术中止血多无并发症,低纤溶部位尤明显。
- 低及部分中等出血风险操作或可不停药,尚需前瞻性研究验证。
核心结论
- FXI/FXIa抑制剂可能成为围手术期理想抗凝药,支持更简单的围术期管理范式。
研究设计与样本
- 综述,汇总FXI缺乏患者手术数据与已完成2期临床试验的围术期数据。
主要发现
- 重大骨科手术静脉血栓预防中,抑制FXI较依诺肝素等现有推荐治疗静脉血栓栓塞风险更低且临床相关出血更少。
- 长期使用FXI抑制剂者行择期操作时,低及部分中等出血风险操作或可不中断用药,较直接口服抗凝药的简化标准化方案更简单且可能更安全。
临床怎么用
- 低及部分中等出血风险择期操作可考虑不中断FXI抑制剂,具体需结合个体评估。
局限性
- 需开展量身定制的围术期前瞻性管理研究、靶向逆转策略及围术期抗凝效应检测方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Factor (F)XI and XIa inhibitors-which include antisense oligonucleotides, monoclonal antibodies, and small peptidomimetic molecules-represent a new class of anticoagulants that inhibit the intrinsic pathway and attenuate thrombosis without disruption of hemostasis, thus making them potentially ideal anticoagulants to use in perioperative settings. Surgical data in patients with FXI deficiency (including severe FXI deficiency) reveal a phenotype that suggests uncomplicated hemostasis, especially in surgical areas of low fibrinolytic activity. Periprocedural data from completed Phase 2 clinical trials demonstrate 2 observations: (1) for primary venous thromboprophylaxis of patients undergoing major orthopedic surgery who are at risk of major bleeding, strategies to inhibit FXI result in a lower risk of venous thromboembolism and lower clinically relevant bleeding compared with current recommended therapy such as enoxaparin; (2) for patients on long-term FXI inhibitors undergoing elective procedures, there is potential for simpler and potentially safer periprocedural paradigms without interruption of FXI inhibitors compared with the simplified and standardized approach with direct oral anticoagulants, at least for low and (some) moderate bleed risk procedures. Further work, including tailored perioperative prospective management studies, targeted FXI inhibitor reversal strategies, and assays to assess the anticoagulant effects of FXI inhibitors in perioperative settings, is needed.
引用
- Spyropoulos AC, Douketis JD. Perioperative management of patients on factor XI or factor XIa inhibitors. J Thromb Haemost. 2026. PMID: 42767508. doi:10.1016/j.jtha.2026.09.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。